Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Vomiting01:22

Pathophysiology of Vomiting

3.4K
Vomiting is a complex physiological response to expel harmful or irritating substances from the body. It's a defensive mechanism triggered by stimuli like poisons, microbial toxins, cytotoxic drugs, and mechanical abdominal distension. The process is centrally coordinated by the vomiting (or emetic) center located in the medulla of the brainstem. This area, rich in muscarinic M1, histamine H1, neurokinin 1 (NK1), and serotonin 5-HT3 receptors, coordinates the act of vomiting through...
3.4K
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

1.1K
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
1.1K
Cholinergic Antagonists: Pharmacological Actions01:28

Cholinergic Antagonists: Pharmacological Actions

1.8K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.8K
Upper Respiratory Drugs: First and Second-Generation Antihistamines01:15

Upper Respiratory Drugs: First and Second-Generation Antihistamines

1.4K
Antihistamines are a class of drugs widely used to alleviate the symptoms of allergies, such as sneezing, itching, and nasal congestion. They work by inhibiting the actions of histamine, which is released by immune cells in response to allergenic substances or tissue injuries.
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
1.4K
Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

5.4K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.4K
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

1.6K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program.

Cephalalgia : an international journal of headache·2026
Same author

Eptinezumab in treatment-resistant chronic migraine: Four-year real-world effectiveness and treatment persistence.

Cephalalgia : an international journal of headache·2026
Same author

Transcultural headache medicine: A framework for integrating cultural contexts into headache science and care - a call to action from the International Headache Society.

Cephalalgia : an international journal of headache·2026
Same author

2025 highlights in non-invasive neurostimulation and neuromodulation for headache management.

Cephalalgia : an international journal of headache·2026
Same author

Revisiting the mechanism of intranasal lidocaine: Evidence beyond sphenopalatine ganglion block.

Headache·2026
Same author

Debunking myths in facial pain diagnosis for the pain practitioner.

Regional anesthesia and pain medicine·2026

Related Experiment Video

Updated: Feb 23, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.8K

Histamine and Migraine.

Hsiangkuo Yuan1, Stephen D Silberstein1

  • 1Jefferson Headache Center, Thomas Jefferson University, Philadelphia, PA, USA.

Headache
|September 2, 2017
PubMed
Summary
This summary is machine-generated.

Histamine plays a key role in migraine development, particularly through neurogenic inflammation. Low-dose histamine shows promise as a migraine prevention strategy, potentially by targeting histamine receptors in the central nervous system.

Keywords:
antihistaminehistaminemigrainetherapeutic

More Related Videos

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

9.9K
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.5K

Related Experiment Videos

Last Updated: Feb 23, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.8K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

9.9K
Investigating Migraine-Like Behavior Using Light Aversion in Mice
05:23

Investigating Migraine-Like Behavior Using Light Aversion in Mice

Published on: August 11, 2021

4.5K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Immunology

Background:

  • Histamine, an ancient tissue amine, is crucial for central nervous system functions like wakefulness and memory.
  • Emerging research suggests histamine's involvement in the pathogenesis and treatment of migraine headaches.
  • Histaminergic fibers in the brain originate from the tuberomammillary nucleus, projecting widely throughout the CNS.

Purpose of the Study:

  • To review the current literature on the role of histamine in migraine pathogenesis.
  • To explore the potential of histamine and its receptors as therapeutic targets for migraine management.

Main Methods:

  • Narrative review of existing scientific literature.
  • Analysis of histamine's interaction with its receptors (H1R, H2R, H3R, H4R) in the context of migraine.

Main Results:

  • Histamine contributes to migraine pathogenesis by sustaining neurogenic inflammation via mast cell and CGRP interactions.
  • Histamine 3 receptor (H3R) and Histamine 4 receptor (H4R) show higher affinity and are potential targets for migraine therapy.
  • Low-dose histamine has demonstrated prophylactic efficacy in preliminary clinical trials, possibly through H3R modulation.

Conclusions:

  • The central nervous system histamine system modulates migraine responses.
  • Low-dose histamine presents a promising therapeutic avenue for migraine prevention.